Investigating new antiviral compounds for HIV treatment
Structural and Chemical Analysis of Highly Potent ALLINI Platform
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11082979
This study is looking at a new type of medicine that could help people with HIV by blocking a key part of the virus's life cycle, aiming to create a safer and more effective treatment that might be easier to stick with over time.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11082979 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new class of antiviral drugs called allosteric integrase inhibitors (ALLINIs) that target HIV-1 integrase, a key enzyme in the HIV life cycle. By blocking specific interactions that facilitate viral replication, these compounds aim to provide a safer and more effective treatment option for patients with HIV. The study explores the mechanisms of these inhibitors and their potential to overcome issues like viral resistance and toxicity associated with current therapies. Patients may benefit from a new long-acting formulation that could improve adherence to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who may be experiencing challenges with current antiretroviral therapies.
Not a fit: Patients who are not living with HIV or those who have already achieved viral suppression with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients living with HIV.
How similar studies have performed: While the concept of ALLINIs is relatively novel, previous research has shown promise in targeting integrase inhibitors, indicating potential for success in this area.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, BAEK — EMORY UNIVERSITY
- Study coordinator: KIM, BAEK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus